Quoin Pharmaceuticals Files 8-K
Ticker: QNRX · Form: 8-K · Filed: May 23, 2025 · CIK: 1671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, financials
Related Tickers: QUOI
TL;DR
QUOI filed an 8-K, standard reporting, no major news.
AI Summary
Quoin Pharmaceuticals, Ltd. filed an 8-K on May 23, 2025, reporting on events that occurred on May 22, 2025. The filing includes financial statements and exhibits, with no specific material events detailed in the provided text beyond the standard reporting requirements.
Why It Matters
This filing indicates routine corporate reporting, providing updates on financial statements and exhibits for Quoin Pharmaceuticals, Ltd.
Risk Assessment
Risk Level: low — The filing appears to be routine administrative and financial reporting, with no immediate indication of significant operational changes or risks.
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — Filer of the 8-K report
- May 22, 2025 (date) — Earliest event date reported
- May 23, 2025 (date) — Filing date of the 8-K
- Cellect Biotechnology Ltd. (company) — Former company name
- Cellect Biomed Ltd. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Quoin Pharmaceuticals, Ltd.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' that occurred or were relevant as of May 22, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on May 23, 2025.
What were Quoin Pharmaceuticals, Ltd.'s former names?
Quoin Pharmaceuticals, Ltd. was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
What is the principal executive office address for Quoin Pharmaceuticals, Ltd.?
The principal executive office address for Quoin Pharmaceuticals, Ltd. is 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.
Does this filing disclose any specific new material events or transactions?
Based on the provided text, this filing primarily concerns routine reporting of financial statements and exhibits, with no specific new material events or transactions detailed.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding Quoin Pharmaceuticals, Ltd. (QNRX).